Peptidoglycan biosynthesis enzymes (Staphylococcus aureus)

Peptidoglycan biosynthesis in Staphylococcus aureus is a multi-step enzymatic process essential for building the bacterial cell wall, which is required for cell viability, morphology, and resistance to osmotic stress. The pathway involves the action of penicillin-binding proteins (PBPs) such as PBP1, PBP2, PBP3, and PBP4, which catalyze peptidoglycan polymerization and cross-linking[5][6][9]. Wall teichoic acid and capsular polysaccharide synthesis further modify the cell wall and are coordinated with peptidoglycan assembly[1][2]. This pathway is the target of many frontline antibiotic classes including β-lactams and glycopeptides, making it crucial for therapeutic intervention against S. aureus infections—including drug-resistant strains such as MRSA[4][6][8]. However, the same essential and multi-component nature of this target means it is better characterized as a pathway or functional group of enzymes, rather than a single molecule. NOTES: - The queried term is not a specific molecule or receptor, but an antibiotic-sensitive biosynthetic pathway. This makes is_incorrect=true for database purposes, since a canonical molecular target should be specified (such as "Penicillin-binding protein 2 (PBP2)" or "MurA enzyme"), rather than a process[5][6][9]. - Nonetheless, Inhibition of bacterial cell wall synthesis in S. aureus is an established therapeutic strategy central to the activity of several major drug classes[8]. - Recommended canonical targets for further resolution would include: "Penicillin-binding protein 2 (PBP2)", "MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)", or specific teichoic acid synthetic enzymes (e.g. TarG)[2][5][7].

Other names

Cell wall synthesis pathwayPeptidoglycan biosynthetic enzymes

Inhibition of peptidoglycan cross-linking (β-lactams), Blockade of cell wall precursor assembly/export (glycopeptides, lipoglycopeptides, WTA inhibitors), Disruption of synthesis enzyme activity